The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL
Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY, talks on the use of tafasitamab for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a monoclonal antibody therapy targeted against CD19 and is used in combination with lenalidomide. Prof. Salles comments on the possibility of curing patients with DLBCL using this therapeutic combination. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
